BioMarin Pharmaceutical Inc. (BMRN)
| Market Cap | 14.13B |
| Revenue (ttm) | 1.86B |
| Net Income (ttm) | 859.10M |
| Shares Out | 180.80M |
| EPS (ttm) | 4.53 |
| PE Ratio | 17.18 |
| Forward PE | 71.43 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | March 5 |
| Last Price | $77.73 |
| Previous Close | $76.35 |
| Change ($) | 1.38 |
| Change (%) | 1.81% |
| Day's Open | 76.28 |
| Day's Range | 74.53 - 77.78 |
| Day's Volume | 1,453,171 |
| 52-Week Range | 68.25 - 131.94 |
Biomarin Pharmaceutical (NASDAQ:BMRN) is currently down 7.49% to a price of $78.33. Friday the stock has been traded at a volume of 86.17 thousand, about 7.66% of its recent 30-day volume aver...
BioMarin (BMRN) beats estimates for both earnings and sales in the fourth quarter. Sales guidance for 2021 falls short of investor expectation.
Biomarin Pharmaceutical (NASDAQ:BMRN) unveils its next round of earnings this Thursday, February 25. Get prepared with Benzinga's ultimate preview for Biomarin Pharmaceutical's Q4 earnings.
SAN RAFAEL, Calif., Feb. 18, 2021 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN), a global leader in providing therapies for rare genetic diseases, today announced the appointment ...
BioMarin (BMRN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Shares in this biotech company are down considerably from where they were this summer, but the stock looks ready to take off again.
TipRanks analyst ranking service pinpoints Wall Street's best-performing stocks, like Intel and BioMarin.
Shares of BioMarin Pharmaceuticals Inc. tumbled 6.6% in trading on Monday, the day after the company shared positive findings from a Phase 3 clinical trial evaluating the experimental drug Roc...
BioMarin (BMRN) announces one-year update from GENEr8-1 phase III study, which shows that valoctocogene roxaparvovec significantly reduces annualized bleeding rate (ABR) by 84% in patients wit...
SAN RAFAEL, Calif., Jan. 10, 2021 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced positive topline results from its ongoing global Phase 3 GENEr8-1 study of valocto...
Our theme of Out Of Favor Health Care Stocks includes health care names that have witnessed strong growth and improving fundamentals over the last few years but have still underperformed over ...
Biopharma deal-making is expected to pick up in 2021 after its slump in 2020, with a good example being AstraZeneca's (AZN) nearly $40 billion purchase of Alexion Pharmaceuticals (ALXN), which...
As markets flirt with record highs, there's more talk about overvalued stocks. However, it's time to consider undervalued stocks.
We discuss a few attractive biotech companies that flaunt solid product portfolios, deep pipelines and lucrative valuations to emerge as likely acquisition targets in 2021.
Eli Lilly and Co. (LLY) recently showed its commitment to gene therapy when it signed a deal that could be worth $2.6 billion with Precision BioSciences Inc. (DTIL).
With 2020 almost over and the new year just two short weeks away, many investors are resetting for what could be a volatile 2021.
These are the biotech stocks with the best value, fastest growth, and most momentum for Q1 2021.
BioMarin (BMRN) reported earnings 30 days ago. What's next for the stock?
New York, New York--(Newsfile Corp. - November 24, 2020) - Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of BioMarin Pharmaceutical Inc. (NASDAQ: BMRN...
LOS ANGELES--(BUSINESS WIRE)---- $BMRN #BMRN--DEADLINE TODAY: The Schall Law Firm Announces it is Investigating Claims Against BioMarin Pharmaceutical Inc.
NEW ORLEANS, Nov. 23, 2020 /PRNewswire/ -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have only ...
New York, New York--(Newsfile Corp. - November 23, 2020) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of BioMarin Pharmaceutical Inc. (...
Los Angeles, California--(Newsfile Corp. - November 23, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against BioM...
New York, New York--(Newsfile Corp. - November 23, 2020) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired secu...
NEW ORLEANS--(BUSINESS WIRE)--ClaimsFiler, a FREE shareholder information service, reminds investors that they have only until November 24, 2020 to file lead plaintiff applications in a securi...
NEW ORLEANS--(BUSINESS WIRE)--Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have only until Novembe...
New York, New York--(Newsfile Corp. - November 20, 2020) - Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of BioMarin Pharmaceutical Inc. (NASDAQ: BMR...
New York, New York--(Newsfile Corp. - November 20, 2020) - Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against BioMarin Pharmaceutical Inc....
LOS ANGELES--(BUSINESS WIRE)-- #classaction--The Law Offices of Frank R. Cruz reminds investors of the upcoming November 24, 2020 deadline to file a lead plaintiff motion in the class action f...
Los Angeles, California--(Newsfile Corp. - November 20, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against BioMa...
Los Angeles, California--(Newsfile Corp. - November 19, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against BioMa...
NEW YORK, Nov. 18, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) between February ...
SAN RAFAEL, Calif. and TORONTO, Nov. 17, 2020 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) and Deep Genomics today announced that the companies have entered into a preclinical c...
BioMarin is a leader in rare disease therapy discovery with multiple competitive advantages including scale, expertise, patents and relationships. Two major catalysts for 2021 provide investor...
Los Angeles, California--(Newsfile Corp. - November 11, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against BioMa...
BioMarin Pharmaceutical Inc. (BMRN) CEO Jean-Jacques Bienaimé on Q3 2020 Results - Earnings Call Transcript
BioMarin (BMRN) beats estimates for both earnings and sales in the third quarter. The company lowers its sales guidance for 2020.
Patient investors could double their money in these two stocks that the market has temporarily cast aside.
The biotech managed to overcome headwinds caused by the COVID-19 pandemic.
BioMarin (BMRN) delivered earnings and revenue surprises of 116.00% and 3.62%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
BMRN stock rose after BioMarin Pharmaceutical late Thursday hiked its earnings guidance for the year. The drug company lowered his sales outlook, but third-quarter sales beat expectations.
New York, New York--(Newsfile Corp. - November 4, 2020) - Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of BioMarin Pharmaceutical Inc. (NASDAQ: BMRN)...
BioMarin Pharmaceutical announced the FDA accepted its new drug application for a proposed treatment for dwarfism, but BMRN stock dipped as investors wary after FDA disappointment in August. T...
Many of us want to forget this year, but investors in these three companies will be especially eager to put 2020 in the rearview mirror.
SAN RAFAEL, Calif., Nov. 2, 2020 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Applicat...
NEW YORK, Oct. 31, 2020 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against BioMarin Pharmaceuticals, Inc. ("BioMarin" or the "Company") (NASDAQ: BMRN) a...
About BMRN
BioMarin Pharmaceutical Inc., a biotechnology company, develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Aldurazyme to treat mucopolysaccharidosis I, a genetic disease; Brineura for the treatment of late infantile neuronal ceroid lipofuscinosis type 2, a form of Batten disease; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commerci... [Read more...]
| Industry Biotechnology | IPO Date Jul 23, 1999 |
| CEO Jean-Jacques Bienaime | Country United States |
| Stock Exchange NASDAQ | Ticker Symbol BMRN |
Analyst Forecasts
According to 23 analysts, the average rating for BMRN stock is "Buy." The 12-month stock price forecast is 107.25, which is an increase of 37.98% from the latest price.